SciBase continues to expand in Germany and Sweden

SciBase, a Swedish medtech company that develops and markets a new technology
for early detection of malignant melanoma, continues to expand. The Company has
contracted an additional selling agent and recruited a further Sales
Representative in Germany, the Companies main market, bringing the total number
of local representatives to five. The Company is also expanding in Sweden and
has recruited Maria Näslund as Product Manager.
- We grow at a faster rate than expected in the German market. We see both an
increased demand for Nevisense and an increased test usage. To be able to manage
this demand we have expanded our presence from three to five persons covering
the German market, says Simon Grant, CEO SciBase.

SciBase has signed an agreement with a new agent with long experience working
with Dermatologists, who will focus on building the Nevisense customer base in
South-West Germany. This is in addition to SciBase’s existing agent and
employees and means that a larger part of Germany now can be covered.

A further new recruitment in Germany will focus on supporting customers as they
incorporate Nevisense into the daily workflow of their clinics - thus increasing
the usage of Nevisense. In practice this means introducing and helping implement
processes that integrate Nevisense into routine clinical care for patients.

- With our business model the bulk of our income comes from the daily use of our
instrument - and that is from the single patient use of electrodes. Therefore it
is important that clinics integrate Nevisense into their daily way of working
and that is something our new sales representatives can support them with, says
Simon Grant

The increased sales resources in Germany are expected to have a positive impact
on the third quarter 2015 and onwards.

SciBase also expands on the home front and has recently recruited Maria Näslund
as the Nevisense Product Manager. Maria will focus on product management and
market support for Nevisense, but will also help drive the development of the
next generation of Nevisense.  Maria worked previously at St Jude Medical in
Uppsala.

For more information, please contact:

Simon Grant, CEO

Phone: +46 72 887 43 99

Email: simon.grant@scibase.com

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB").
Avanza is Certified Adviser. Further information is available on
www.scibase.com.